Paclitaxel-Coated Balloon Versus Zotarolimus-Eluting Stent for Treatment of De Novo Coronary Artery Lesions

Exclusion Criteria

• •1. Myocardial infarction (\< 7 days);
• •2. Heavy thrombotic burden in target vessel;
• •3. eGFR \< 30ml/min or hemodialysis patients;
• •4. Other cardiovascular and cerebrovascular procedures planned within 12 months after index PCI;
• •5. Patients with contraindications to antiplatelet agents and anticoagulants or bleeding tendency, history of active peptic ulcer, and stroke within 6 months;
• •6. Life expectancy of less than 1 years;
• •7. Patient is a woman who is pregnant or nursing;
• •8. Known allergic to medications such as Aspirin, Heparin, antiplatelet drugs, paclitaxel, or contrast; patients with systemic lupus erythematosus or other systemic immune diseases;
• •9. Chronic total occlusion lesion;
• •10. Unprotected left main disease;
• •11. Bifurcation lesion requiring 2 stents;
• •12. Ostial lesions, distance from left main ≤ 2mm;
• •13. Severe calcification or distortion;
• •14. Arterial, venous or prosthetic grafts;
• •15. In-stent stenosis requiring revascularization (defined as stenosis≥50% by visual or positive functional assessments in any vessel);
• •16. Myocardial bridging located at target lesions;
• •17. Currently participating in another trial and not yet at its primary endpoint;
• •18. Participants deemed unsuitable to be enrolled by investigators for unable to comply with protocol or other reasons.